SGLT2 inhibitors in heart failure with reduced ejection fraction

被引:0
|
作者
Uday Sankar Das
Aritra Paul
Suvro Banerjee
机构
[1] Apollo Gleneagles Hospitals,
[2] Nil Ratan Sircar Medical College and Hospital,undefined
[3] Apollo Gleneagles Hospitals,undefined
来源
The Egyptian Heart Journal | / 73卷
关键词
Heart failure; Reduced ejection fraction; SGLT2 inhibitors; Diabetes; Renal disease;
D O I
暂无
中图分类号
学科分类号
摘要
Sodium – glucose co-transporter 2 (SGLT2) inhibitors reduce blood glucose by inhibiting reabsorption of glucose from the proximal renal tubules. Initial studies showed that apart from reducing blood glucose they also reduce the combined endpoint of myocardial infarction, stroke, and cardiovascular death, hospitalization from heart failure, and occurrence of renal failure in patients with known cardiovascular disease or at high risk of developing cardiovascular disease. Recent studies have shown that these drugs also could be used in patients to treat heart failure or to slow the progression of renal failure, irrespective of whether the patients have diabetes or not. In this review, we discuss the clinical trial evidence for the use of SGLT2 inhibitors for the treatment of patients with heart failure with reduced ejection fraction and for the prevention of heart failure in patients with diabetes who are at high risk of cardiovascular events. We also discuss the plausible mechanisms of action for the cardiovascular beneficial effects of SGLT2 inhibitors. EMPA-REG OUTCOME TRIAL, DECLARE-TIMI 58, CANVAS, VERTIS-CV studies have shown that SGLT2 inhibitors namely empagliflozin, dapagliflozin, canagliflozin and ertugliflozin reduce the chances of hospitalisation in patients who have cardiovascular disease or at high risk of cardiovascular disease. The DAPA-HF study and the EMPEROR-REDUCED TRIAL have further shown that Dapagliflozin and Empagliflozin could be used to treat patients with heart failure, with or without diabetes. SGLT2 inhibitors provide us with a new armamentarium for treatment of patients with a triad of diabetes, heart or renal disease. Their mechanism of action in prevention or treatment of patients with heart failure however still remains speculative.
引用
收藏
相关论文
共 50 条
  • [21] Do sglt2 inhibitors improve survival in heart failure with any ejection fraction?
    Yi, Ko
    Wong, Suzanne
    Wong, Kenneth
    Al-riyahi, Mohammad
    HEART, 2023, 109 : A175 - A177
  • [22] Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
    Pabel, Steffen
    Hamdani, Nazha
    Singh, Jagdeep
    Sossalla, Samuel
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [23] Are SGLT2 inhibitors effective against 'all' heart failure with preserved ejection fraction?
    Hasegawa, Koji
    Lewis, Basil S.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022,
  • [24] Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
    Rebecca Heath
    Håkon Johnsen
    W. David Strain
    Marc Evans
    Diabetes Therapy, 2022, 13 : 241 - 250
  • [25] Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction
    Packer, Milton
    Cleland, John G. F.
    Bauersachs, Johann
    EUROPEAN HEART JOURNAL, 2024, 45 (25) : 2186 - 2196
  • [26] Eligibility and prescribing rates of SGLT2 inhibitors for ambulatory patients with heart failure and reduced ejection fraction in a multidisciplinary heart failure management programme
    Nadarajah, R.
    Younis, A.
    Aktaa, S.
    Gale, C. P.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [27] The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
    Starr, Jessica A.
    Pinner, Nathan A.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (05) : 506 - 513
  • [28] Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
    Schneider, Christian A.
    Pfister, Roman
    HERZ, 2022, 47 (05) : 395 - 400
  • [29] SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know
    Stephen J. Greene
    Gregg C. Fonarow
    Javed Butler
    American Journal of Cardiovascular Drugs, 2024, 24 : 1 - 4
  • [30] SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting
    Merlo, Anna
    D'Elia, Emilia
    Di Odoardo, Luca
    Sciatti, Edoardo
    Senni, Michele
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2025, 27 : i137 - i140